top of page

1 Non-Contrast Scan              10+ Actionable Reports

Cardiovascular

Health

CardioMetabolic 

Health

Lung Health

Bone Health

All-in-one AI-CVD

497e6f54-782b-4e077a-3a7144e4f3e4.png

AutoFracture

(coming soon)

upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
0bdba309-a76a-4215-b207-90a7932bb681.png
iScreen Shoter - 20260520111737117 1.png
Frame 1000004271.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520100645073 1.png

Explore AI-Powered Solutions & See Real AI reports

See More. Detect Earlier. Treat Better. Earn More.

Icon1.png
Quantitative Results

Detailded measurments 

and biomarks

Detailded measurments 

and biomarks

Icon1.png
Annotated Images

See AI segmentation and

overlays

Icon1.png
Clinical Reports

Clear, actionable, and

physician-ready insights.

Icon1.png
Longitudinal Tracking

Monitor patient progress

over time

AI-driven analysis of cardiac chamber volumes provides actionable insights into heart failure and atrial fibrillation risk.

AI-CAC Finding

iScreen Shoter - 20260618194404455.jpg

Accuracy

Icon1.png
DICOM Preview

Interactive viewer and

comparison

Icon1.png
Longitudinal Tracking

Monitor patient progress

over time

A Paradigm Shit in

CVD Risk Assessment

AI-CVD® is an advanced artificial intelligence technology that extracts opportunistic screening information available in a cardiac or lung CT scan. This innovative approach significantly enhances CVD risk stratification by integrating imaging disease measures. AI-CVD® thus emerges as the most comprehensive tool that extends well beyond coronary artery calcium (CAC) score and coronary artery disease to enable physicians to predict heart failure, atrial fibrillation, stroke, total CVD, CVD death and all-cause mortality.

Key Components of AI-CVD Developed by Heartlung

Beyond the CAC Score

The size of the aorta and pulmonary artery (PA) are key indicators of cardiovascular health. Changes in PA size can signal pulmonary hypertension or other vascular diseases. Accurate measurement through imaging helps in early detection and management. An enlarged aorta can indicate conditions like aneurysm or dissection. AI-CVD™ uses advanced algorithms to measure these sizes, enhancing risk assessment and timely intervention for cardiovascular and pulmonary conditions.

Myosteatosis, characterized by fat infiltration into skeletal muscle, is an emerging biomarker of systemic metabolic dysfunction. AI-driven measurement of thoracic skeletal muscle density from CAC scans has shown strong predictive value for HF, AF, CHD), and all-cause mortality. Recent studies demonstrate that combining myosteatosis with CAC scores amplifies risk prediction, particularly for males, making it a critical addition to AI-CVD™.

Thoracic vertebral bone density, measurable in routine CAC scans, provides an important marker for osteoporosis. Low BMD is independently associated with increased CVD risk and all-cause mortality, potentially mediated by shared inflammatory and metabolic pathways. Incorporating BMD into CVD risk assessments ensures early detection of both osteoporosis and its cardiovascular implications, enabling timely interventions. 

AutoLiver

Fatty liver, detected opportunistically in CAC scans, correlates with metabolic syndrome, diabetes, and heightened CVD risk. By quantifying liver fat, AI-CVD™ identifies individuals at risk for cardiometabolic events, offering opportunities for early lifestyle or pharmacological interventions.

AVC, visible in CAC scans, predicts aortic stenosis and its associated cardiovascular outcomes. Early identification of AVC facilitates closer monitoring and timely surgical or medical interventions, reducing morbidity and mortality from valve-related complications.

Pulmonary emphysema, visible in chest CT scans, is linked to chronic obstructive pulmonary disease (COPD) and increased cardiovascular mortality. Including emphysema scoring in AI-CVD™ highlights the interplay between pulmonary and cardiovascular health, fostering integrated care approaches.

AI-driven analysis of cardiac chamber volumes—including the left atrium (LA), left ventricle (LV), right atrium (RA), and right ventricle (RV) provides actionable insights into heart failure and atrial fibrillation risk. Enlarged LA volume strongly predicts AF and stroke, while LV hypertrophy correlates with HF and coronary artery disease. These measurements add critical dimensions to CAC scans, improving predictive accuracy.

AI-CVD®: The Most Comprehensive CVD CT Screening 

CVD Risk Assessment

AI-CVD® leverages advanced AI algorithms to enable physicians evaluate cardiovascular disease risk that is otherwise missed. This approach significantly improves the prediction of conditions like heart failure and atrial fibrillation, outperforming traditional risk scores. Validated through studies like MESA and FHS, AI-CVD® aims to set a new standard in preventive cardiology.​

New Design AI-CVD Report.png

Sign Up For A Free Trial

How did you hear about us? Required

Thank you for your interest in AI-CVD®.A HeartLung representative will contact you as soon as possible!

Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page